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Summary
Background No assessment of the National Bowel Screening Program (NBCSP) in Australia, which considers all 
downstream benefits, costs, and harms, has been done. We aimed to use a comprehensive natural history model and 
the most recent information about cancer treatment costs to estimate long-term benefits, costs, and harms of the 
NBCSP (2 yearly immunochemical faecal occult blood testing screening at age 50–74 years) and evaluate the 
incremental effect of improved screening participation under different scenarios.
Methods In this modelling study, a microsimulation model, Policy1-Bowel, which simulates the development of 
colorectal cancer via both the conventional adenoma-carcinoma and serrated pathways was used to simulate the 
NBCSP in 2006–40, taking into account the gradual rollout of NBCSP in 2006–20. The base-case scenario assumed 
40% screening participation (currently observed behaviour) and two alternative scenarios assuming 50% and 
60% participation by 2020 were modelled. Aggregate year-by-year screening, diagnosis, treatment and surveillance-
related costs, resource utilisation (number of screening tests and colonoscopies), and health outcomes (incident 
colorectal cancer cases and colorectal cancer deaths) were estimated, as was the cost-effectiveness of the NBCSP.
Findings With current levels of participation (40%), the NBCSP is expected to prevent 92 200 cancer cases and 
59 000 deaths over the period 2015–40; an additional 24 300 and 37 300 cases and 16 800 and 24 800 deaths would be 
prevented if participation was increased to 50% and 60%, respectively. In 2020, an estimated 101 000 programme-
related colonoscopies will be done, associated with about 270 adverse events; an additional 32 500 and 
49 800 colonoscopies and 88 and 134 adverse events would occur if participation was increased to 50% and 60%, 
respectively. The overall number needed to screen (NNS) is 647–788 per death prevented, with 52–59 colonoscopies 
per death prevented. The programme is cost-effective due to the cancer treatment costs averted (cost-effectiveness 
ratio compared with no screening at current participation, AUS$3014 [95% uncertainty interval 1807–5583] per life-
year saved) in the cost-effectiveness analysis. In the budget impact analysis, reduced annual expenditure on colorectal 
cancer control is expected by 2030, with expenditure reduced by a cumulative AUS$1·7 billion, AUS$2·0 billion, and 
AUS$2·1 billion (2015 prices) between 2030 and 2040, at participation rates of 40%, 50%, and 60%, respectively.
Interpretation The NBCSP has potential to save 83 800 lives over the period 2015–40 if coverage rates can be increased 
to 60%. By contrast, the associated harms, although an important consideration, are at a smaller magnitude at the 
population level. The programme is  highly cost-effective and within a decade of full roll-out, there will be reduced 
annual health systems expenditure on colorectal cancer control due to the impact of screening.
Funding Australia Postgraduate Award PhD Scholarship, Translational Cancer Research Network Top-up scholarship 
(supported by Cancer Institute NSW) and Cancer Council NSW.
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Introduction
Colorectal cancer is the third most common cancer in 
Australia and the second most common cause of cancer 
death, with 14 962 new cases of bowel cancer diagnosed 
and 4149 bowel cancer deaths reported in 2013.1 Most 
colorectal cancer cases (>90%) are diagnosed in 
individuals aged 50 years or older and the disease is more 
common in men than in women.1 Due to the high burden 
of disease and the availability of new treatments 
for advanced cancer, the costs related to treatment are 
considerable, and have increased substantially over the 
past decade to an estimated AUS$1 billion annually in 
2013.2 Additionally, there are major costs associated 
with colonoscopy, sometimes used for ad-hoc screening, 
with an estimated 700 000 colonoscopies (for all purposes) 
done in 2012 in Australia.3
Screening with the faecal occult blood test (FOBT) has 
been shown to be effective in reducing bowel cancer 
incidence and mortality in long-term cohort follow up 
and in trials.4 In Australia, the National Bowel Cancer 
Screening Program (NBCSP) was introduced in late 
2006, offering free immunochemical faecal occult blood 
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testing (iFOBT) for Australians turning 55 years and 
65 years in that year.5 The programme has been 
expanding since then, via the addition of new age cohorts. 
The programme will be fully rolled out by 2020, at which 
stage it will offer biennial screening to all people aged 
50–74 years. However, in the period between 2006 and 
2019, some age cohorts will have been screened at a 
longer interval (for example, the birth cohort who 
received the first screening invitation at the age of 
55 years in 2006 were eligible for the second screening 
invitation in 2016).5 In 2013–14, about 2·3 million iFOBT 
test kits were sent by the NBCSP to eligible Australians 
(individuals aged 50 years, 55 years, 60 years, and 
65 years) and 836 457 kits were completed and returned 
to the programme (yielding a participation rate of about 
37·3%).5 The reported overall positivity rate of the 
completed iFOBT tests was 7·0%.5
Three modelling or economic studies have been done 
to evaluate biennial iFOBT screening for people aged 
50–74 years in Australia, but none of these have taken into 
account the effect of screening and surveillance on all 
downstream health and cost outcomes; and no analysis, 
to the best of our knowledge, to date has accounted for 
the rapid increase in colorectal cancer treatment costs in 
the past two decades.2,6–8 A summary of the findings of 
these three studies is shown in the appendix.
The aims of this study were therefore to derive an 
accurate and updated estimate of the benefits, harms, 
resource use, annual expenditure, and cost-effectiveness 
of the fully implemented NBCSP in Australia over the 
period between 2015 and 2040, taking into account the 
effect of gradual rollout of the screening programme 
before 2020, the most current data for cancer treatment 
costs, and the effect of downstream management, 
including colonoscopy surveillance, on both the effects 
and costs of the programme; and to assess the effect of 
improved screening participation on these outcomes.
Methods
Model calibration and validation
We used the Policy1-Bowel microsimulation platform, 
which was developed by adapting and recalibrating an 
existing colorectal cancer natural history model, the 
Adenoma and Serrated Pathway to Colorectal CAncer 
model (ASCCA),9 to natural history data and the 
Australian setting. The Policy1-Bowel model was 
constructed using Microsoft Visual Studio 2013 C++.
The model simulates 10 million men and 10 million 
women per single year age cohort, and incorporates sex-
specific life table data. The simulation begins from age 
20 years and continues on an annual time-step until the 
individual dies or becomes 90 years old, whichever occurs 
Research in context
Evidence before this study
Screening with the faecal occult blood test has been found to be 
effective in reducing bowel cancer incidence and mortality in 
long-term cohort follow-up and in trials. In Australia, the National 
Bowel Cancer Screening Program (NBCSP) was introduced in late 
2006 and will be fully rolled out by 2020, at which stage it will 
offer biennial screening with free immunochemical faecal occult 
blood testing (iFOBT) to all people aged 50–74 years. The overall 
participation rate was 37% in 2013–14. Colorectal cancer 
treatment costs in Australia have increased rapidly in the past two 
decades. We searched PudMed and MEDLINE in 
March to April, 2016, to identify economic evaluations of biennial 
iFOBT screening in individuals aged 50–74 years in Australia. The 
literature review identified three modelling or health economics 
studies. However, no assessment that takes into account the 
effect of screening and surveillance on all downstream health and 
cost outcomes and the rapid increase in colorectal cancer 
treatment costs has been done.
Added value of this study
We did a comprehensive evaluation of the long-term benefits, 
costs, and harms of the NBCSP using a well calibrated and 
validated model, Policy1-Bowel. The model took into account 
both the conventional adenoma-carcinoma pathway and the 
serrated pathway in the natural history of colorectal cancer 
development, the phased implementation of NBCSP in the 
period 2006–20, the detailed management pathways for 
screening and colonoscopy surveillance, and the observed 
screening behaviour. The model also incorporated all the 
downstream benefits, costs, and harms of the NBCSP and the 
most recent information about cancer treatment costs, which 
have been rapidly increasing in Australia, in the cost-
effectiveness evaluation. The study provided detailed 
predictions of the number of colorectal cancer cases, colorectal 
cancer deaths, the overall NBCSP programme cost, and resource 
use (including number of iFOBT test kits sent and returned to 
the programme, programme-related colonoscopies, and 
adverse events) that would occur in the period between 2006 
and 2040.
Implication of all the available evidence
Our study findings suggest that the NBCSP in Australia will be 
very effective in reducing colorectal cancer mortality, and its 
effectiveness would be further increased with improved 
participation. The NBCSP was found to be highly cost-effective 
in the cost-effectiveness analysis, which involves discounting 
costs and effects over the lifetime of a single cohort. Findings 
from the (undiscounted) budget impact analysis for each year 
showed that the total annual cost to the health system to 
provide iFOBT screening, colonoscopy follow-up and 
surveillance, and colorectal cancer treatment would become less 
than the total cost without screening within a decade of full 
rollout of the programme in 2020, due mainly to avoidance of 
treatment costs for colorectal cancer.
See Online for appendix
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first. The multiple cohort implementation simulates 
cohorts turning 20 years from 1911 to 2000, to obtain a full 
cross-sectional outcome in the population in the period 
between 2000 and 2059. As is the case for the ASCCA 
model,9 Policy1-Bowel includes both the conventional 
adenoma-carcinoma pathway and serrated pathway in 
colorectal cancer development and is calibrated to the 
prevalence of lesions observed in the colonoscopy arm of 
the COCOS trial,10 a Dutch trial of colorectal screening 
with colonoscopy and CT colonography, which was 
done in screening-naive individuals. For Policy1-Bowel, 
the precancer natural history assumptions were 
systematically recalibrated using the Nelder-Mead 
algorithm; target data included the age-specific, sex-
specific, and size-specific prevalence of conventional 
adenoma, advanced con ventional adenoma and serrated 
lesions, the relative proportions by degree of dysplasia and 
degree of villosity in conventional adenoma, and relative 
proportions of conventional adenoma multiplicity, 
advanced conventional adenoma multiplicity, and serrated 
lesion multiplicity among individuals detected with polyps 
observed in the COCOS trial. The model-predicted age-
specific and age-standardised rates of colorectal cancer 
incidence and mortality in an unscreened population 
were calibrated to pre-NBCSP Australian data (appendix 
pp 40–43).11 The least-squares method was used to examine 
the goodness of fit of the natural history solutions; the 
best fitting set of natural history assumptions was selected 
for base case analysis, and the top 200 best fitted natural 
history sets were selected for alternative natural history 
assumptions in uncertainty analysis (appendix pp 32–40).
The model was also calibrated to a number of aspects 
specific to colorectal cancer and to the NBCSP in Australia. 
In brief, the test characteristics of iFOBT were based on 
the literature and then calibrated to the observed iFOBT 
positivity rate and the colonoscopy outcomes among those 
with a positive iFOBT result, as observed each year in 
the NBCSP in 2006–14 (appendix pp 43–44).12–16 The 
accuracy of colonoscopy for adenoma and cancer detection 
was based on the findings of two systematic reviews and 
calibrated to the proportion of the colonoscopy outcomes 
observed among positive iFOBT individuals in the 
NBCSP.14,17,18 Detailed information about the modelled 
iFOBT and colonoscopy test characteristics are provided 
in the appendix (pp 19–23).
The modelled invasive cancer natural history and 
cancer detection rates for iFOBT and colonoscopy were 
calibrated to predict cancer stage distributions among 
symptomatically detected cancers and screen-detected 
cancers that are consistent with the findings of a 2009 
Australian study (appendix p 41).19 The final cancer 
survival probabilities thus varied by stage at diagnosis, 
time since diagnosis, and whether cancer was diagnosed 
via screening or symptomatically detected. The modelled 
cancer stage-specific relative survival between screen-
detected and symptomatically detected cancers were 
consistent with the findings of international studies.20–22 
These final calibrated survival assumptions assumed that 
within-stage survival is slightly worse for symptomatically 
detected cancers versus screen-detected cancers, which is 
clinically plausible.20–22 Detailed information about 
natural history calibration methods and outcomes, model 
Figure 1: Modelled screening participation in 2006–2059, all participation scenarios
Individuals aged 55 years and 65 years were invited to participate in colorectal screening during NBCSP phase 1 in 2006–08; 50 years, 55 years, and 65 years were 
invited during phase 2 in 2008–13; 50 years, 55 years, 60 years, and 65 years were invited during phase 3 in 2013–14; 50 years, 55 years, 60 years, 65 years, 70 years, 
and 74 years were invited during NBCSP phase 4 in 2015; 50 years, 55 years, 60 years, 64 years, 65 years, 70 years, 72 years, and 74 years were invited during phase 4 
in 2016; 50 years, 54 years, 55 years, 58 years, 60 years, 64 years, 68 years, 70 years, 72 years, and 74 years will be invited during phase 4 in 2017; 50 years, 54 years, 
58 years, 60 years, 62 years, 64 years, 66 years, 68 years, 70 years, 72 years, and 74 years will be invited during phase 4 in 2018; 50 years, 52 years, 54 years, 56 years, 
58 years, 60 years, 62 years, 64 years, 66 years, 68 years, 70 years, 72 years ,and 74 years will be invited for screening during phase 4 in 2019 and after the NBCSP 
programme is fully implemented in 2020. NBCSP= National Bowel Screening Programme.
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validation outcomes, natural history assumptions, cancer 
survival assumptions, and other model parameters are 
provided in the appendix (pp 9–49).
Screening participation and colonoscopy compliance 
assumptions
The Policy1-Bowel model simulated the phased 
implementation of NBCSP in 2006–19 and the fully 
implemented biennial iFOBT screening programme 
for 50–74 years from 2020 onwards (see appendix 
pp 5–7 for the detailed programme rollout schedule).12 
Figure 1 shows the modelled participation rate for those 
invited, from the inception of the programme. For each 
calendar year from 2006 onward, the model assumed 
that all individuals who are eligible for screening will 
be sent an iFOBT kit. The number of individuals 
eligible for a NBCSP invitation each year is estimated to 
increase from 421 735 in 2006 to about 3·6 million by 
2020, and to 4·7 million by 2040 (see appendix p 5 for 
more detail on the estimated number of individuals 
eligible for an NBCSP invitation in each year).23,24 We 
used NBCSP data to directly inform the modelled 
assumptions for the age-specific and sex-specific 
screening initiation rate among individuals who had 
never participated in the past (33–40%), taking into 
account the observed changes in these rates, which 
occurred as the programme rolled out between 2006 
and 2014.12 We also used NBCSP data to directly inform 
the modelled age-specific and sex-specific re-screening 
rate (about 74%) for those who had previously 
participated in the NBCSP at least once.12
From 2015, three alternative participation scenarios 
assuming different screening initiation rates were 
evaluated; screening re-attendance rates were assumed to 
remain at a similar level from 2015 onwards in all 
scenarios. Scenario 1 assumed that overall 2-yearly 
screening participation in the NBCSP, which includes a 
re-screening rate from the so-called ever-screened group 
and a screening initiation rate from the so-called 
never-screened group, remained at about 40% for 2020 
onwards. Scenarios 2 and 3 modelled an increase in 
overall screening participation by assuming an increase in 
initiation rates from 2016 onwards. In scenario 2, the 
overall population participation rate assumed in the 
model was about 50% by 2020, increasing thereafter, 
becoming stable at around 60% by 2035, with the delay in 
realising the full effect being due to that associated with 
the delayed effect of the increase in screening initiation on 
subsequent overall re-screening rates (since 74% of people 
who had previously accepted an invitation to screen in the 
programme will re-screen).5 For scenario 3, the modelled 
overall screening participation was increased to about 
60% by 2020, leading to a fully realised increased coverage 
rate of about 70% by 2035. Detailed information about the 
screening initiation and ongoing participation 
assumptions and the data sources to inform these 
assumptions are provided in the appendix (pp 23–29).
Individuals with a positive iFOBT outcome were 
assumed to be referred to colonoscopy (and polypectomy 
if required). Colonoscopy surveillance was modelled 
based on the individual’s colonoscopy outcome and 
surveillance guideline recommendations.26,27 Screening 
and colon oscopy surveillance were assumed to cease at 
75 years. The colonoscopy attendance rate for individuals 
with a positive iFOBT was assumed to be 71% in those 
aged 50–74 years, as reported for the NBCSP.15 The 
attendance rate for further colonoscopy surveillance to 
follow up individuals with lesions originally detected by 
screening was assumed to be 80%. We assumed that 
colonoscopy was associated with a serious non-fatal 
adverse event rate of up to 0·27% (2·7 per 1000 procedures 
in the base case we assumed no fatal adverse events; for 
more detail on the justification of the assumed 
colonoscopy adverse event rate see the appendix 
[pp 22–23]).
Costs
Using a health services perspective, costs considered 
included those associated with iFOBT, follow-up of 
positive iFOBT results, colonoscopy (and polypectomy if 
required), and colorectal cancer treatment; overheads 
related to administration and promotion of the screening 
programme and individuals’ out-of-pocket costs were 
not included. Detailed information and a summary of 
the aggregate cost assumptions is provided in the 
appendix (pp 17–18). Costs were obtained from the 
Australian Medical Benefits Schedule (MBS) and the 
Australian-refined Diagnostic Related Group (AR-DRG) 
categories, where applicable, and after consultation with 
experts (DJBSJ, PG), assumptions were made for the 
iFOBT kit and postage cost, as well as the cost of each kit 
received and analysed in the laboratory, and the cost of 
colonoscopy (without complications). The costs 
associated with cancer treatment were based on previous 
data and inflated to 2015 values;7 these cost assumptions 
are consistent with the findings of a recent Australian 
study that found colorectal cancer treatment costs 
increased substantially over the past two decade.2 All 
costs are presented in 2015 Australian dollars 
(AUS$1=US$0·7706, June 20, 2015). It should be noted 
that the model assumed iFOBT test kits were sent to all 
alive individuals of an eligible age (regardless of the 
individual’s screening history) every year; hence this 
particular expenditure was independent of screening 
adherence assumptions. Cost-effectiveness ratios (CERs) 
were compared with no screening and referenced to the 
relevant indicative willingness-to-pay (WTP) threshold 
in Australia—AUS$50 000 per life-year saved (or quality-
adjusted life-year saved).
Single and multiple cohort analyses
The health outcomes and costs of the NBCSP were 
evaluated using two approaches—single cohort analysis, 
which provides lifetime outcomes for a single birth cohort 
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of both sexes, and multiple cohort analysis, which provides 
cross-sectional outcomes over time. The single cohort 
analysis assessed the effect of the fully implemented 
biennial screening programme by comparing the lifetime 
cost and health outcomes of a birth cohort that is eligible 
to participate in the fully implemented biennial iFOBT 
programme from the age of 50 years (ie, screened cohort) 
with a birth cohort that has never been screened with 
iFOBT (ie, never-screened cohort). Three screened 
birth cohorts, each associated with different 2-yearly 
participation rates of 40% (scenario 1), 60% (scenario 2), 
and 70% (scenario 3), for ages 50–74 years, were evaluated 
(in the single cohort analysis, these rates were chosen to 
reflect the maximum cross-sectional participation 
expected to be achieved by 2035 as shown in figure 1).
A cost-effectiveness analysis was done using the overall 
life-time cost and life-years in a single cohort, which were 
accrued from 50 to 89 years and discounted at a rate of 5% 
starting at 50 years, the age when bowel cancer screening 
begins.28 The CER was calculated by dividing the difference 
of the discounted lifetime cost by the difference of the 
discounted life-years between the screened and never-
screened cohort. We used the same perspective, discount 
rate and WTP threshold as per a predicate Medical Services 
Advisory Committee (MSAC) evaluation of the National 
Cervical Screening Program.29 The age-standardised rates 
of colorectal cancer incidence and mortality 
were estimated using the standard 2001 Australian popu-
lation.23 The base case analysis assumed the best fitted set 
for natural history assumptions; the 200 alternative fitted 
sets were used to quantify uncertainty due to the natural 
history assumptions and outcomes were presented as 
95% uncertainty intervals (UI). To assess the robustness of 
the findings due to uncertainties in screening and 
management, univariate sensitivity analysis was also done 
on a number of key model assumptions for the findings 
for the CER of screening when compared with no 
screening in scenario 1 (appendix pp 9–11).
The multiple cohort analysis was used to estimate 
aggregate year-by-year screening, diagnosis, treatment, 
and surveillance-related costs, resource use (number of 
iFOBT tests sent, number returned, and number of 
colonoscopies), and health outcomes (incident colorectal 
cancer cases and colorectal cancer deaths) in the period 
2000–59. Model-estimated age-specific rates for each year 
were applied to the 2000–13 Australian population and 
the projected 2013–60 populations.23,24 The budget impact 
analysis was done using undiscounted cost outcomes 
from the multiple cohort analysis. The number-needed-
to-screen (NNS) to prevent one colorectal cancer 
case/death was calculated by dividing the total number of 
iFOBT kits returned by the total number of colorectal 
cancer cases/deaths prevented in 2015–40. The number-
needed-to-colonoscope (NNC) to prevent one colorectal 
cancer case/death was calculated by dividing the total 
number of colonoscopies by the total number of 
colorectal cancer cases/deaths prevented in 2015–40.
Role of the funding source
The study sponsors took no part in designing the study 
question or in the analysis or interpretation of results. 
They also did not take part in the writing of the Article 
or in the decision to submit for publication. The 
corresponding author had full access to all the data in 
the study and had final responsibility for the decision 
to submit for publication.
Results
Over the lifetime of a cohort, biennial iFOBT screening 
between 50 years and 74 years was estimated to reduce 
colorectal cancer incidence by 23% (95% UI 20–24) and 
colorectal cancer mortality by 36% (32–38), respectively, 
when assuming the current 40% participation rate 
(scenario 1; table 1). A greater reduction in both cancer 
incidence (33% and 38%, respectively) and mortality 
(52% and 59%, respectively) were estimated if the 
participation was increased to 60% (scenario 2) or 70% 
(scenario 3). Scenarios assuming higher screening 
participation rates were associated with a higher overall 
proportion of early stage, screen-detected cancers. After 
screening and surveillance cease at 75 years, screened 
cohorts are predicted to experience an ongoing further 
Colorectal cancer 
incidence rate per 
100 000 individuals*
Colorectal cancer 
mortality rate per 
100 000 individuals*
Discounted cost per 
person,† base case‡ (AUS$; 
95% UI)§¶
Discounted life-years per 
person,† base case‡ 
(95% UI)§¶
Base case 
ASR‡
% reduction, 
base case‡ (95% 
UI)§¶
Base 
case 
ASR‡
% reduction, 
base case‡ (95% 
UI)§¶
No screening 62·6 ·· 22·9 ·· $1653 (1468– 1881) 15·571 (15·552– 15·590)
Scenario 1, 40% participation 48·4 23% (20–24) 14·6 36% (32–38) $1732 (1682– 1937) 15·597 (15·579–15·614)
Scenario 2, 60% participation 41·9 33% (29–35) 11·0 52% (47–55) $1761 (1727– 1958) 15·610 (15·594– 15·626)
Scenario 3, 70% participation 39·0 38% (33–39) 9·5 59% (53–61) $1798 (1769– 1989) 15·617 (15·602 –15·632)
UI=uncertainty interval. ASR=age-standardised rate. *Assuming 2001 Australian population, all ages. †Discounted at 5% per annum starting at 50 years (the age when bowel 
cancer screening begins), accrued from 50 years to 89 years. ‡Used best-fitting set of natural history assumptions. §Compared with no screening. ¶95% UI generated via 
200 runs with alternative sets of calibrated natural history assumptions.
Table 1: Single cohort analysis findings of health outcomes and costs over the lifetime of a cohort
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decrease in cancer incidence and mortality over the next 
5 years (appendix pp 50–51).
Compared with the indicative WTP threshold of 
AUS$50 000 per life-years saved, all base case scenarios 
found that biennial iFOBT screening is cost-effective 
compared with no screening in the cost-effectiveness 
analysis. The predicted CER was AUS$3014 per life-years 
saved in scenario 1, AUS$2693 per life-years saved in 
scenario 2, and AUS$3048 per life-years saved in 
scenario 3 when compared with no screening (figure 2). 
In the natural history uncertainty analysis, biennial 
iFOBT screening was predicted to be cost-effective in all 
runs of the three scenarios; the 95% UIs of the CERs of 
screening were estimated to be AUS$1807–5583 per 
life-years saved in scenario 1, AUS$1543–5195 per life-
years saved in scenario 2, and AUS$1830–5611 per 
life-years saved in scenario 3 when compared with no 
screening (figure 2).
The estimated age-standardised colorectal incidence and 
mortality rates and cancer stage distributions for each year 
in the period between 2005 and 2050 are provided in the 
appendix (pp 52–53). Taking into account the age-structure 
of the Australian population over time, about 
12 600 incident colorectal cancer cases and 4600 colorectal 
cancer deaths were predicted in 2005. Under the no 
screening assumption, by 2040, the numbers would 
increase to 29 900 incident cases and 11 200 deaths 
(figure 3). A lesser magnitude for the increase in the 
number of incident colorectal cancer cases and colorectal 
cancer deaths over time was predicted in the screening 
scenarios. Over a short-term period from 2015 to 2019, the 
NBCSP was predicted to detect an additional 4800–7900 
colorectal cancer cases and to prevent 1900–2000 colorectal 
cancer deaths depending on the assumed screening 
participation rate (table 2). An additional 97 000–137 400 
colorectal cancers and 57 100–81 800 colorectal cancer 
deaths are predicted to be prevented in the two decades 
after the biennial iFOBT screening is fully implemented in 
2020 (depending on participation). This is equivalent to an 
average 3500–5000 colorectal cancer cases and 2300–3200 
colorectal cancer deaths prevented per year in the period 
2015–40.
In the (undiscounted) budget impact analysis, the 
overall expenditure on treatment for colorectal cancer was 
estimated to be AUS$858 million in 2006, increasing to 
about AUS$1 billion by 2010 and about AUS$2 billion by 
2040 in the no screening scenario (2015 prices). This 
increase in expenditure occurs even in the absence of 
additional treatment advances or other changes in average 
treatment costs and is due to growth and ageing of the 
population (figure 3). The commencement of the NBCSP 
is predicted to result in a transient increase in overall 
expenditure in 2006–28, but a reduced annual expenditure 
on colorectal cancer control from 2029 onwards is 
expected in all screening participation scenarios. The 
total expenditure was estimated to be reduced by a 
cumulative AUS$1·7 billion, AUS$2·0 billion, and 
AUS$2·1 billion (2015 prices) between 2030 and 2040, at 
participation rates of 40%, 50%, and 60%, respectively 
(predicted from data in figure 3C). Notably, although the 
NBCSP is predicted to be associated with a lower annual 
expenditure than no screening in long term, it is predicted 
to be highly cost-effective (but not cost-saving) in the 
single cohort analysis when discounted costs and 
discounted life-years were used to estimate the cost-
effectiveness ratio (table 1).
Over the period 2015–40, we estimate about 99 million 
iFOBT test kits will be sent out to eligible individuals 
(figure 3E). Depending on screening participation, 
38–66 million test kits will be returned for further 
analysis and 3·1–5·0 million individuals will undergo 
colonoscopy (figure 3; table 2). This is equivalent to an 
average of 1·5–2·5 million individuals being screened 
by iFOBT and 118 300–191 300 individuals undergoing 
colonoscopy each year in that period (table 2). The 
estimated average number of colonoscopies per year 
increased to 134 500 in scenario 1, 193 900 in scenario 2, 
and 223 800 in scenario 3 over a 40-year period between 
2015 and 2054. The number of non-fatal colonoscopy-
related adverse events was estimated to increase over 
time as the number of colonoscopies increased. An 
average of 320–520 adverse events a year was estimated 
in 2015–40 (table 2).
Over the period 2015–40, an NNS of 414, 480, and 
510, respectively, and an NNC of 33, 37, and 38, 
respectively, was estimated in scenarios 1, 2, and 3 to 
prevent one colorectal cancer case; the associated NNS 
was 647, 737, and 788, respectively, and the associated 
NNC was 52, 57, and 59, respectively, to prevent one 
colorectal cancer death.
In sensitivity analysis, the CER of screening 
(compared with no screening) was found to be most 
sensitive to the potential range of cancer treatment costs 
Figure 2: Probabilistic sensitivity analysis for cost-effectiveness for all scenarios
Scenario 1=40% participation; Scenario 2=60% participation; Scenario 3=70% participation. The CER of screening 
was estimated to be AUS$3014 (95% UI 1807–5583) per life-year saved in Scenario 1, AUS$2693 (1543–5195) per 
life-year saved in Scenario 2, and AUS$3048 (1830–5611) per life-year saved in Scenario 3, compared with no 
screening. NH=natural history.
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(CER range: AUS$1439–11 463 per life-years saved) and 
colonoscopy costs (the base case colonoscopy 
assumption, including specialist visit for colonoscopy 
procedure, polypectomy and the relevant histopathology 
tests, was AUS$1800; screening was predicted to 
become cost-saving when colonoscopy was assumed to 
cost AUS$1440; CER of screening was AUS$6380 
per life-years saved when colonoscopy was assumed to 
cost AUS$2500). The CER was found to be moderately 
sensitive to alternative assumptions about colonoscopy 
lesion detection rates, colonoscopy-related deaths, 
relative survival for screen-detected versus 
symptomatically detected cancer, and iFOBT test kit 
costs, but not to the other parameters examined in the 
sensitivity analysis. The detailed findings of the 
sensitivity analysis are provided in the appendix 
(pp 59–60).
Discussion
Our results indicate that the NBCSP is highly cost-
effective. In the multiple cohort analysis, even at the 
current relatively low levels of participation, the NBCSP is 
Figure 3: Predicted health outcomes, costs, and resource use over the period 2005–59
(A) Number of incident colorectal cancer cases, (B) number of colorectal cancer deaths, (C) total cost, (D), breakdown of total costs in 2040, (E) number of iFOBT kits 
sent/returned, and (F) number of individuals undergoing colonoscopy. iFOBT=immunochemical faecal occult blood test. COL=colonoscopy. *Cost associated with 
iFOBT screening includes cost of iFOBT test kits sent to eligible individuals, laboratory procedures to analyse returned iFOBT test kits from participants; return 
postage; cost associated with follow-up of individuals with a positive iFOBT result with colonoscopy (and polypectomy if required), including cost of general 
practitioner visit after positive iFOBT result, specialist visit for colonoscopy procedure, polypectomy, and the relevant histopathology tests; cost associated with 
colonoscopy surveillance for individuals who previously had adenomas detected and removed by polypectomy includes cost of specialist visit for colonoscopy 
procedure, polypectomy and the relevant histopathology tests. 
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expected to prevent at least 92 200 colorectal cancer cases 
and 59 000 deaths over the next 25 years. If participation 
rates of 60% or more were achieved for the target 
population, which is consistent with what has been 
achieved in the organised cervical and breast cancer 
screening programmes in Australia, the number of cases 
prevented and lives saved from this highly cost-effective 
programme would increase even further. In the budget 
impact analysis, the annual expenditure on colorectal 
cancer control is predicted to become less than in the 
absence of screening within a decade of full roll-out; this 
will occur when the very substantial savings in cancer 
treatment costs start to be realised.
The strength of this analysis is that it uses a 
comprehensive and extensively calibrated model of colo-
rectal cancer natural history that incorporates two 
biological pathways of colorectal cancer—the conven-
tional adenoma-carcinoma pathway and the serrated 
pathway. We comprehensively assessed the effect of 
uncertainty and the main findings were found to be 
robust under a range of assumptions. Furthermore, the 
model takes into account the phased implementation of 
NBCSP in the period 2006–20, detailed colonoscopy 
follow-up and surveillance management pathways, and 
the observed screening behaviour in Australia, and 
incorporates colorectal cancer treatment costs that are 
consistent with the latest estimates,2,7 which have rapidly 
increased in the past two decades.
A limitation, by necessity, was that a number of 
influential parameters related to future screening 
practice were based on assumptions. However, we 
explored a range of potential future participation 
scenarios and the assumptions were conservative with 
respect to follow-up colonoscopy compliance rates. The 
modelled compliance rate to colonoscopy follow-up 
after positive iFOBT (about 71%) was derived from the 
current rate reported in Australia. This number is likely 
to be an underestimate of the actual compliance rate 
due to under-reporting of attendance in the context of 
non-mandatory reporting of colonoscopy to the NBCSP 
register.12 As for previous modelled analyses in other 
settings, the screening participation was assumed to be 
2015–19 2020–40 2015–54
Model estimates Compared with no screening Model estimates Compared with no screening Model estimates Compared with no screening
Total number of incident colorectal cancer cases*
No screening 86 400 ·· 516 400 ·· 1 067 000 ··
Scenario 1 91 200 4800 additional cases detected 419 400 97 000 cases prevented 856 900 210 100 cases prevented
Scenario 2 93 900 7500 additional cases detected 392 400 124 000 cases prevented 783 200 283 800 cases prevented
Scenario 3 94 400 7900 additional cases detected 379 000 137 400 cases prevented 747 300 319 700 cases prevented
Total number of colorectal cancer deaths*
No screening 31 600 ·· 191 800 ·· 397 800 ··
Scenario 1 29 700 1900 deaths prevented 134 700 57 100 deaths prevented 272 400 125 300 deaths prevented
Scenario 2 29 700 1900 deaths prevented 117 900 73 900 deaths prevented 228 900 168 800 deaths prevented
Scenario 3 29 600 2000 deaths prevented 110 000 81 800 deaths prevented 209 200 188 500 deaths prevented
Total screening, diagnosis, treatment, and surveillance related costs
No screening $5·7 billion ·· $34·4 billion ·· $71·1 billion ··
Scenario 1 $6·7 billion $1·0 billion additional cost $33·3 billion $1·1 billion less $67·6 billion $3·5 billion less
Scenario 2 $7·1 billion $1·3 billion additional cost $33·5 billion $884 million less $66·9 billion $4·2 billion less
Scenario 3 $7·1 billion $1·4 billion additional cost $33·8 billion $589 million less $66·8 billion $4·4 billion less
Total number of iFOBT tests returned
Scenario 1 4·7 million NA 33·5 million NA 66·5 million NA
Scenario 2 6·0 million NA 49·8 million NA 99·5 million NA
Scenario 3 6·3 million NA 59·7 million NA 118·1 million NA
Total number of individuals undergoing colonoscopy*
Scenario 1 358 300 NA 2·7 million NA 5·4 million NA
Scenario 2 446 700 NA 3·9 million NA 7·8 million NA
Scenario 3 462 200 NA 4·5 million NA 9·0 million NA
Total number of colonoscopy-related non-fatal adverse events
Scenario 1 967 NA 7335 NA 14 524 NA
Scenario 2 1206 NA 10 485 NA 20 945 NA
Scenario 3 1248 NA 12 201 NA 24 169 NA
Currency is AUS$. iFOBT=immunochemical faecal occult blood testing. NA=not applicable. *Numbers are rounded to the nearest hundred.
Table 2: Estimated total health outcomes, overall costs, resource use, and adverse events over the periods 2015–19, 2020–40, and 2015–54
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independent of an individual’s underlying risk of 
cancer development in the model.25 Although we 
incorporated the latest available data for treatment 
costs, this might further increase in future due to new 
innovations in the use of therapeutic agents or 
investigation methods.2 Furthermore, we did not 
consider the longer term cost savings due to a potential 
decrease in iFOBT kit and postage costs. We also did 
not consider the programme administrative costs (other 
than the costs of sending test kits) in the analysis. The 
estimated CER associated with screening would be 
likely to increase with addition of programme 
administrative costs, although these costs are likely to 
scale linearly with participation rates. However, 
although we note these limitations about future 
assumptions, the modelled outcomes show a good 
correspondence with programme outcomes to date (a 
detailed discussion of the comparison between 
modelled data and the observed outcomes of the 
NBCSP in terms of the iFOBT test positivity rate, 
estimated programme sensitivity and colonoscopy 
outcomes can be found in the appendix [pp 43–44]). As 
further data become available about future screening 
behaviour and health services and cancer treatment 
costs, such data can be incorporated into updated 
analyses.
Our finding that biennial iFOBT screening is highly 
cost-effective when compared with no screening is 
consistent with other international cost-effectiveness 
evaluations,30,31 some of which have even found iFOBT 
screening to be cost-saving32–34 (see appendix [pp 62–63] 
for a detailed comparison with the findings of other key 
modelled evaluations internationally). To the best of our 
knowledge, our analysis, however, is the first in Australia 
to take into account all costs and benefits of the NBCSP, 
although a number of previous Australian evaluations 
have been done.6,7,35–37 These generally found that 
biennial FOBT screening was cost-effective, but 
estimated much higher values for the cost-effectiveness 
ratio, from AUS$25 000–54 000 per life-years saved6,7 
compared with our estimate of AUS$3014 (95% UI 
1807–5583) per life-years saved (given current 
participation). The differences are probably due to a 
range of factors, but most prominently among these is 
our incorporation of the greatly increased bowel cancer 
treatment costs, particularly for advanced cancer 
(consistent with the recent estimates2). Compared with 
previous research,8 our findings predict more lives will 
be saved by the NBCSP; a previous study estimated that 
70 038 deaths would be prevented between 2015 and 
2055 when assuming 40% screening participation. 
Modelling over the same period and with similar 
participation assumptions, we estimate that 
125 300 deaths will be prevented. We extensively 
calibrated and validated our model against the NBCSP 
outcomes to 2014. Differences in the results between 
studies are probably due to a range of factors, including 
different underlying natural history assumptions in the 
micro simulation models used, and we also accounted 
for improved stage-specific cancer survival for screen-
detected versus sympto matically detected cancers, 
which is consistent with international findings.20–22
The Policy1-Bowel platform is now able to be 
harnessed to consider a range of important policy 
questions for the NBCSP in Australia, including the use 
of alternative iFOBT test thresholds, technologies, and 
alternate screening age ranges, and in the future can be 
used to assess the possible role of a risk-based approach 
to screening, wherein individuals are screened 
according to their a-priori risk of developing colorectal 
cancer in their lifetime (see appendix pp 64–65 for 
further discussion). However, in terms of the current 
programme, we show that a relatively modest increase 
in participation in the programme will have an 
enormous effect on the cumulative burden of disease 
over the next 25 years; with 83 800 deaths preventable in 
that period. These findings underpin the need to 
continue efforts to increase participation in the 
programme and show that the NBCSP is one of the 
most cost-effective and life-saving public health 
programmes in Australia.
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